Bioloomics leverages activity-guided antibody library screening through Synthetic Biology, AI, Imaging, and Robotics to build a therapeutic pipeline of anti-cancer therapies.

Bioloomics

BioLoomics is a preclinical stage biotechnology company leveraging directed evolution of antibodies in human cells to create ADCs with improved internalization and trafficking. Our proprietary tech combines single-cell bioassay engineering, robotics, and ML. 
#synbio #directedevolution #antibodies #ADCs

BioLoomics

BioLoomics is all about evolution...even our lab space. 
We were once one bench at CU Boulder, then in a founder's garage, then in two separate FLEX spaces. Along the way, we have collected the do's and don't for a successful lab design. 

We recently began building a new HQ in the West Flatiron Park where we will bring together our operation in a brand new state of the art lab. 

Special thanks to Patrick Brady, CCIM, Sharon Wilhelm, and Craig Lemle at Savills for helping us navigate the real estate ecosystem in Boulder, CO, to our very own Nicole Beach for managing and heading up this lab build out, and to our architect Ethan Hampton.  

This is the blank canvas today that will morph into a BSL1 and BSL2 antibody drug conjugate optimization lab:

We Welcome Kurt Gish as the Chief Scientific Officer (CSO) of BioLoomics. 

👉 Kurt is an ADC Expert
👉 He Has Successfully Taken ADC Programs to The Clinic
👉 He is an Inspiring Person & Great Leader

We Are Excited to Have You On Board!

#ADCs, #Biotech

https://lnkd.in/ga6443xC

We're #hiring a new Scientist I -- Protein Expression & Purification in Boulder, Colorado. Apply today or share this post with your network.

BioLoomics welcomes Dr. Chris Bahl as a scientific advisor! 

Dr. Bahl is the President, CSO, and Co-founder of AI Proteins. Dr. Bahl pioneered the ability to computationally design miniproteins de novo as a postdoctoral fellow with Dr. David Baker at the University of Washington’s Institute for Protein Design in Seattle. Following his post-Doc, he joined the Institute for Protein Innovation in Boston as one of the founding faculty members, with co-appointments at Boston Children’s Hospital and Harvard Medical School. Dr. Bahl is an expert in the state-of-the-art computational tools for protein design, which BioLoomics is leveraging to climb the fitness landscape across multiple activities for antibody chimeras. We are super excited to work with you!

Learn more about AI Proteins at aiproteins.bio
Hear Chris’s Ted talk at https://lnkd.in/giXDPkjN
Learn more about BioLoomics at www.bioloomics.com

#Biologics #ADCs #TargetedProteinDegradation

BioLoomics welcomes Dr. Jeanne Stachowiak as a scientific advisor! 

Dr. Stachowiak is a jointly appointed professor of Chemical Engineering and the Department of Biomedical Engineering at the University of Texas at Austin. Her research into how proteins and lipids interact at the cell membrane has highlighted the power of biophysical activities like phase separation in endocytosis, receptor sorting, and membrane curvature sensing/generation. Dr. Stachowiak has unique insights into the protein design principles that underly membrane interaction that will aid our development of antibodies with programmable trafficking to the lysosome. We are super excited to work with you!

Learn more about Jeanne and her research at www.stachowiaklab.org
Learn more about BioLoomics at www.BioLoomics.com

#Biologics, #ADCs, #TargetedProteinDegradation

Thank You Calvin Chen at WuXi Biologics for inducting BioLoomics into the Enable the Molecule Program. 

This innovative program will accelerate our ability to generate and optimize candidate antibodies through fast paced Phage Display, Cell & Animal Studies, Etc. We are excited to work together on this journey to bring novel antibody degraders and more to unmet areas of therapeutic need!

Metric
Company Name	Bioloomics
Symbol
MSH ID	COM:BIOLOOMICS
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count	17
Website	bioloomics.com
LinkedIn	bioloomics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:BIOLOOMICS

Bioloomics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue